This website is managed by Ultima Markets’ international entities, and it’s important to emphasise that they are not subject to regulation by the FCA in the UK. Therefore, you must understand that you will not have the FCA’s protection when investing through this website – for example:
You will not be guaranteed Negative Balance Protection
You will not be protected by FCA’s leverage restrictions
You will not have the right to settle disputes via the Financial Ombudsman Service (FOS)
You will not be protected by Financial Services Compensation Scheme (FSCS)
Any monies deposited will not be afforded the protection required under the FCA Client Assets Sourcebook. The level of protection for your funds will be determined by the regulations of the relevant local regulator.
Note: UK clients are kindly invited to visit https://www.ultima-markets.co.uk/. Ultima Markets UK expects to begin onboarding UK clients in accordance with FCA regulatory requirements in 2026.
If you would like to proceed and visit this website, you acknowledge and confirm the following:
1.The website is owned by Ultima Markets’ international entities and not by Ultima Markets UK Ltd, which is regulated by the FCA.
2.Ultima Markets Limited, or any of the Ultima Markets international entities, are neither based in the UK nor licensed by the FCA.
3.You are accessing the website at your own initiative and have not been solicited by Ultima Markets Limited in any way.
4.Investing through this website does not grant you the protections provided by the FCA.
5.Should you choose to invest through this website or with any of the international Ultima Markets entities, you will be subject to the rules and regulations of the relevant international regulatory authorities, not the FCA.
Ultima Markets wants to make it clear that we are duly licensed and authorised to offer the services and financial derivative products listed on our website. Individuals accessing this website and registering a trading account do so entirely of their own volition and without prior solicitation.
By confirming your decision to proceed with entering the website, you hereby affirm that this decision was solely initiated by you, and no solicitation has been made by any Ultima Markets entity.
隨著 AI 技術滲透醫療產業,Tempus AI(NASDAQ: TEM)憑藉龐大的臨床與基因數據庫迅速崛起,被視為 AI 精準醫療領域的重要指標股。不過,TEM美股仍處於虧損狀態,加上估值偏高,使投資人同時看見機會與風險。步入 2026 年,隨著公司與超過 95% 的全球領先藥廠建立數據授權合作,其「數據即服務 (DaaS)」模式展現了極高的護城河。本文將從商業模式、財務結構、歷史市場反應到實際交易思維,全面解析 TEM美股是否值得佈局。
TEM美股與AI精準醫療概念
Tempus AI(TEM)是什麼?
Tempus AI 是一家以 AI 分析醫療數據、協助臨床決策的科技公司。Tempus AI 成立於 2015 年,專注整合基因測序、臨床紀錄與 AI 演算法,協助醫師制定更個人化的治療方案,尤其深耕腫瘤醫療市場,這也是 TEM美股能被歸類為「AI 醫療核心概念股」的關鍵。(延伸閱讀:新手必看10檔ETF與績優股完整指南)
公司背景與願景
Tempus AI 的創立源於真實醫療痛點。創辦人 Eric Lefkofsky 因家人抗癌經驗,意識到臨床決策缺乏數據支撐,進而建立 Tempus,希望透過 AI 將醫療「經驗判斷」轉為「數據決策」,這一理念也成為 TEM美股長線敘事的根基。
Thank you for visiting the Ultima Markets website. Please note that this website is intended for individuals residing in jurisdictions where accessing is permitted by law. Ultima and its affiliated entities do not operate in your home jurisdictions.
By clicking on ''Acknowledge'', you confirm that you are entering this website solely based on your initiative and not as a result of any specific marketing outreach. You wish to obtain information from this website based on reverse solicitation principles, in accordance with the applicable laws of your home jurisdiction.